List of Tables
    Table 1. Myasthenia Gravis Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Myasthenia Gravis Drugs Market Trends
    Table 3. Myasthenia Gravis Drugs Market Drivers
    Table 4. Myasthenia Gravis Drugs Market Challenges
    Table 5. Myasthenia Gravis Drugs Market Restraints
    Table 6. Global Myasthenia Gravis Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Myasthenia Gravis Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Myasthenia Gravis Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Myasthenia Gravis Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Myasthenia Gravis Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Myasthenia Gravis Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Myasthenia Gravis Drugs Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Myasthenia Gravis Drugs Sales by Manufacturer, (MT), 2017-2022
    Table 14. Global Myasthenia Gravis Drugs Sales Share by Manufacturer, 2017-2022
    Table 15. Global Myasthenia Gravis Drugs Price by Manufacturer (2017-2022) & (USD/Kg)
    Table 16. Global Myasthenia Gravis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Myasthenia Gravis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myasthenia Gravis Drugs as of 2021)
    Table 18. Top Players of Myasthenia Gravis Drugs in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Myasthenia Gravis Drugs Product Type
    Table 20. Date of International Manufacturers Enter into Myasthenia Gravis Drugs Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Myasthenia Gravis Drugs Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Myasthenia Gravis Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Myasthenia Gravis Drugs Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Myasthenia Gravis Drugs Sales by Players, (MT), 2020, 2021 & 2022
    Table 26. United States Myasthenia Gravis Drugs Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Myasthenia Gravis Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Myasthenia Gravis Drugs Sales in Volume by Region (2017-2022) & (MT)
    Table 29. Global Myasthenia Gravis Drugs Sales in Volume Forecast by Region (2023-2028) & (MT)
    Table 30. Global Myasthenia Gravis Drugs Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Myasthenia Gravis Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Myasthenia Gravis Drugs Sales in Volume by Country (2017-2028) & (MT)
    Table 33. North America Myasthenia Gravis Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Myasthenia Gravis Drugs Sales in Volume by Region (2017-2028) & (MT)
    Table 35. Asia Pacific Myasthenia Gravis Drugs Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Myasthenia Gravis Drugs Sales in Volume by Country (2017-2028) & (MT)
    Table 37. Europe Myasthenia Gravis Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Myasthenia Gravis Drugs Sales in Volume by Country (2017-2028) & (MT)
    Table 39. Latin Americaa Myasthenia Gravis Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Myasthenia Gravis Drugs Sales in Volume by Country (2017-2028) & (MT)
    Table 41. Middle East and Africa Myasthenia Gravis Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Flamel Technologies Corporation Information
    Table 43. Flamel Technologies Description and Business Overview
    Table 44. Flamel Technologies Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 45. Flamel Technologies Myasthenia Gravis Drugs Product
    Table 46. Flamel Technologies Recent Development
    Table 47. F. Hoffmann-La Roche Corporation Information
    Table 48. F. Hoffmann-La Roche Description and Business Overview
    Table 49. F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 50. F. Hoffmann-La Roche Product
    Table 51. F. Hoffmann-La Roche Recent Development
    Table 52. Grifols Corporation Information
    Table 53. Grifols Description and Business Overview
    Table 54. Grifols Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 55. Grifols Product
    Table 56. Grifols Recent Development
    Table 57. Pfizer Corporation Information
    Table 58. Pfizer Description and Business Overview
    Table 59. Pfizer Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 60. Pfizer Product
    Table 61. Pfizer Recent Development
    Table 62. Takeda Corporation Information
    Table 63. Takeda Description and Business Overview
    Table 64. Takeda Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 65. Takeda Product
    Table 66. Takeda Recent Development
    Table 67. Novartis Corporation Information
    Table 68. Novartis Description and Business Overview
    Table 69. Novartis Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 70. Novartis Product
    Table 71. Novartis Recent Development
    Table 72. Bausch Health Corporation Information
    Table 73. Bausch Health Description and Business Overview
    Table 74. Bausch Health Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 75. Bausch Health Product
    Table 76. Bausch Health Recent Development
    Table 77. Alexion Pharmaceuticals Corporation Information
    Table 78. Alexion Pharmaceuticals Description and Business Overview
    Table 79. Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 80. Alexion Pharmaceuticals Product
    Table 81. Alexion Pharmaceuticals Recent Development
    Table 82. Catalyst Pharmaceuticals Corporation Information
    Table 83. Catalyst Pharmaceuticals Description and Business Overview
    Table 84. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 85. Catalyst Pharmaceuticals Product
    Table 86. Catalyst Pharmaceuticals Recent Development
    Table 87. CSL Corporation Information
    Table 88. CSL Description and Business Overview
    Table 89. CSL Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 90. CSL Product
    Table 91. CSL Recent Development
    Table 92. Curavac Corporation Information
    Table 93. Curavac Description and Business Overview
    Table 94. Curavac Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 95. Curavac Product
    Table 96. Curavac Recent Development
    Table 97. Cytokinetics Corporation Information
    Table 98. Cytokinetics Description and Business Overview
    Table 99. Cytokinetics Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 100. Cytokinetics Product
    Table 101. Cytokinetics Recent Development
    Table 102. Galencia Corporation Information
    Table 103. Galencia Description and Business Overview
    Table 104. Galencia Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 105. Galencia Product
    Table 106. Galencia Recent Development
    Table 107. GlaxoSmithKline Corporation Information
    Table 108. GlaxoSmithKline Description and Business Overview
    Table 109. GlaxoSmithKline Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 110. GlaxoSmithKline Product
    Table 111. GlaxoSmithKline Recent Development
    Table 112. Lupin Pharmaceuticals Corporation Information
    Table 113. Lupin Pharmaceuticals Description and Business Overview
    Table 114. Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 115. Lupin Pharmaceuticals Product
    Table 116. Lupin Pharmaceuticals Recent Development
    Table 117. Mitsubishi Tanabe Pharma Corporation Information
    Table 118. Mitsubishi Tanabe Pharma Description and Business Overview
    Table 119. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
    Table 120. Mitsubishi Tanabe Pharma Product
    Table 121. Mitsubishi Tanabe Pharma Recent Development
    Table 122. Key Raw Materials Lists
    Table 123. Raw Materials Key Suppliers Lists
    Table 124. Myasthenia Gravis Drugs Customers List
    Table 125. Myasthenia Gravis Drugs Distributors List
    Table 126. Research Programs/Design for This Report
    Table 127. Key Data Information from Secondary Sources
    Table 128. Key Data Information from Primary Sources
List of Figures
    Figure 1. Myasthenia Gravis Drugs Product Picture
    Figure 2. Global Myasthenia Gravis Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Myasthenia Gravis Drugs Market Size 2017-2028 (US$ Million)
    Figure 4. Global Myasthenia Gravis Drugs Sales 2017-2028 (MT)
    Figure 5. United States Myasthenia Gravis Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Myasthenia Gravis Drugs Market Size 2017-2028 (US$ Million)
    Figure 7. United States Myasthenia Gravis Drugs Sales 2017-2028 (MT)
    Figure 8. United States Myasthenia Gravis Drugs Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Myasthenia Gravis Drugs Market Share in Global, in Volume (MT) 2017-2028
    Figure 10. Myasthenia Gravis Drugs Report Years Considered
    Figure 11. Product Picture of Anticholinesterases
    Figure 12. Product Picture of Immunosuppressants
    Figure 13. Product Picture of Intravenous Immune Globulins
    Figure 14. Global Myasthenia Gravis Drugs Market Share by Type in 2022 & 2028
    Figure 15. Global Myasthenia Gravis Drugs Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 16. Global Myasthenia Gravis Drugs Sales Market Share in Value by Type (2017-2028)
    Figure 17. Global Myasthenia Gravis Drugs Sales by Type (2017-2028) & (MT)
    Figure 18. Global Myasthenia Gravis Drugs Sales Market Share in Volume by Type (2017-2028)
    Figure 19. Global Myasthenia Gravis Drugs Price by Type (2017-2028) & (USD/Kg)
    Figure 20. United States Myasthenia Gravis Drugs Market Share by Type in 2022 & 2028
    Figure 21. United States Myasthenia Gravis Drugs Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 22. United States Myasthenia Gravis Drugs Sales Market Share in Value by Type (2017-2028)
    Figure 23. United States Myasthenia Gravis Drugs Sales by Type (2017-2028) & (MT)
    Figure 24. United States Myasthenia Gravis Drugs Sales Market Share in Volume by Type (2017-2028)
    Figure 25. United States Myasthenia Gravis Drugs Price by Type (2017-2028) & (USD/Kg)
    Figure 26. Product Picture of Hospitals
    Figure 27. Product Picture of Clinics
    Figure 28. Global Myasthenia Gravis Drugs Market Share by Application in 2022 & 2028
    Figure 29. Global Myasthenia Gravis Drugs Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 30. Global Myasthenia Gravis Drugs Sales Market Share in Value by Application (2017-2028)
    Figure 31. Global Myasthenia Gravis Drugs Sales by Application (2017-2028) & (MT)
    Figure 32. Global Myasthenia Gravis Drugs Sales Market Share in Volume by Application (2017-2028)
    Figure 33. Global Myasthenia Gravis Drugs Price by Application (2017-2028) & (USD/Kg)
    Figure 34. United States Myasthenia Gravis Drugs Market Share by Application in 2022 & 2028
    Figure 35. United States Myasthenia Gravis Drugs Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 36. United States Myasthenia Gravis Drugs Sales Market Share in Value by Application (2017-2028)
    Figure 37. United States Myasthenia Gravis Drugs Sales by Application (2017-2028) & (MT)
    Figure 38. United States Myasthenia Gravis Drugs Sales Market Share in Volume by Application (2017-2028)
    Figure 39. United States Myasthenia Gravis Drugs Price by Application (2017-2028) & (USD/Kg)
    Figure 40. North America Myasthenia Gravis Drugs Sales in Volume Growth Rate 2017-2028 (MT)
    Figure 41. North America Myasthenia Gravis Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 42. U.S. Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Canada Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Europe Myasthenia Gravis Drugs Sales in Volume Growth Rate 2017-2028 (MT)
    Figure 45. Europe Myasthenia Gravis Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 46. Germany Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 47. France Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 48. U.K. Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Italy Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Russia Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Asia-Pacific Myasthenia Gravis Drugs Sales in Volume Growth Rate 2017-2028 (MT)
    Figure 52. Asia-Pacific Myasthenia Gravis Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 53. China Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Japan Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. South Korea Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. India Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Australia Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Taiwan Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Indonesia Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Thailand Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Malaysia Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Philippines Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Latin America Myasthenia Gravis Drugs Sales in Volume Growth Rate 2017-2028 (MT)
    Figure 64. Latin America Myasthenia Gravis Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 65. Mexico Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Brazil Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Argentina Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Middle East & Africa Myasthenia Gravis Drugs Sales in Volume Growth Rate 2017-2028 (MT)
    Figure 69. Middle East & Africa Myasthenia Gravis Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 70. Turkey Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Saudi Arabia Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. U.A.E Myasthenia Gravis Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Myasthenia Gravis Drugs Value Chain
    Figure 74. Myasthenia Gravis Drugs Production Process
    Figure 75. Channels of Distribution
    Figure 76. Distributors Profiles
    Figure 77. Bottom-up and Top-down Approaches for This Report
    Figure 78. Data Triangulation
    Figure 79. Key Executives Interviewed